

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (CDF Review of TA559)

For public – AIC, CIC and cPAS redacted

Technology appraisal committee C [06 December 2022]

Chair: Richard Nicholas

Lead team: Natalie Hallas, Alex Cale, Ugochi Nwulu

Evidence assessment group: Kleijnen Systematic Reviews

Technical team: Lewis Ralph, Vicky Kelly, Ross Dent

Company: Kite, a Gilead Company

NICE

© NICE 2022. All rights reserved. Subject to [Notice of rights](#).

Recap: Summary of original appraisal (TA559) and CDF Review



ID3980 Decision: The committee were satisfied with the company model. Company and ERG base case analyses were consistent and was appropriate for decision making. Committee would have preferred to have seen longer-term PFS data but acknowledged constraints within the trial design. Would have also preferred more sensitivity analyses around utility values in “cured” patients.

Remaining decision-impacting uncertainty limited to the cost of delivering CAR-T therapy on the NHS

- Company used a bottom-up costing approach using sources commonly used in technology appraisals but argued to not capture increased staff time required for CAR-T
- NHSE tariff more costly than the company approach – Implications for cost effectiveness

To address uncertainties, further data was provided by NHSE. Tariff reduced from £96k to £61k at ACM2. Concerns of double counting in scenarios run with £61k tariff.

ACM1 base case results – includes original axi-cel PAS

ERG and company base case aligns, not including tariff

Deterministic incremental base case results – presented at ACM1

Technology	Total costs (£)	Total QALYs	Incremental costs (£)	Incremental QALYs	ICER (£/QALY)
BSC	████████	████			
Axi-cel	████████	████	████████	████	████████

Results with original axi-cel PAS, █████%

Deterministic incremental base case results – post-ACM1*

Technology	Total costs (£)	Total QALYs	Incremental costs (£)	Incremental QALYs	ICER (£/QALY)
BSC	████████	████			
Axi-cel	████████	████	████████	████	████████

Results with original axi-cel PAS, █████%

*The NICE technical team identified an error in the company’s model regarding length of stay during administration and the company provided an updated model

Updated company analysis

- At ACM2, the committee considered a cost of £60,000 appropriate for delivering CAR-T therapy.
- However, concerns still remained about the potential for double counting in the analysis
 - Namely, costs included in the NHSE tariff that were separately accounted for by the company's bottom-up costing approach
- The company proposed a new analysis, using a £41,101 (in line with the EAG analysis seen in ID1684)
 - Removing all other costs relevant to the delivery of CAR-T for the first 100 days following infusion
- NHSE have accepted this as a total cost for the first 100 days and recommend NICE consider this in all ongoing CAR-T appraisals
- Since ACM2, the company has increased the axi-cel PAS to ██████%, accepted by NHSE

Cost category	Model value set to £0 for analysis
Axi-cel leukapheresis costs	████████████████████
Hospitalisation costs for conditional chemotherapy	████████████████████
Weighted average cost of CRS	████████████████████
Hospitalisation costs for axi-cel administration	████████████████████
Axi-cel costs for weighted average cost of allogenic SCT	████████████████████
Training costs	████████████████████
Medical resource use costs for the first 3 months (~100 days)	████████████████████
Hypogammaglobulinemia costs for the first 3 months (~100 days)	████████████████████
Total costs removed for £41,101 analysis by Gilead	████████████████████

Updated results – includes updated axi-cel PAS

ERG and company base case aligns, including tariff

Deterministic incremental base case results – post-ACM1 including tariff

Technology	Total costs (£)	Total QALYs	Incremental costs (£)	Incremental QALYs	ICER (£/QALY)
BSC	████████	████			
Axi-cel	████████	████	████████	████	████████

Results with updated axi-cel PAS, ██████%

Updated results – includes updated axi-cel PAS

ERG and company base case aligns, including tariff

Deterministic incremental base case results – post-ACM1 including tariff

Technology	Total costs (£)	Total QALYs	Incremental costs (£)	Incremental QALYs	ICER (£/QALY)
BSC	████████	████			
Axi-cel	████████	████	████████	████	████████

Results with updated axi-cel PAS, ██████%

Thank you.